Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.
Target Price
The average target price of ARMP is 15 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell